Introduction {#S1}
============

Affecting human populations in the whole world, cancer is a disease that can virtually compromise all biological human tissues. More than 18 million new cases of cancer were expected for 2018 and more than 9 million patients died in the same year ([@B15]; [@B32]). Other than different factors distinguishing particular cancer types, metastasis is considered to be the most important cause of death related to this disease and patients affected by metastasis at diagnosis can present a reduced survival rate of 60--90% ([@B48]; [@B6]).

Tumor metastasis is a multistep process through which cancer cells leave their primary site to colonize distant organs ([@B125]; [@B83]; [Figure 1](#F1){ref-type="fig"}). In order to migrate and invade, epithelial cancer cells undergo phenotypic alterations to detach from surrounding cells, degrade the basement membrane and remodel the extracellular matrix (ECM) in a process known as epithelial-mesenchymal transition (EMT) ([@B78]). These cancer cells will reach blood or lymph vessels and then proceed to vasculature intravasation. Some of the circulating tumor cells (CTCs) which survive into blood or lymph will adhere to vessel walls and escape from the vessel lumen by vasculature extravasation ([@B57]; [Figure 1](#F1){ref-type="fig"}). Still, while mesenchymal cells present enhanced ability to invade different tissues and proceed to vasculature intravasation/extravasation during metastasis, this phenotype impairs their establishment in a secondary site, limiting the growth of macrometastasis ([Figure 1](#F1){ref-type="fig"}). Thus, after reaching a new organ, neoplastic cells reverse their phenotype through the mesenchymal-epithelial transition (MET), improving their interaction with the microenvironment and increasing their proliferation rate and chance of survival ([@B17]; [@B14]). Therefore, the two opposite processes of EMT and MET in metastasis early and late-stages, respectively, are considered to be critical steps in cancer metastasis.

![Cancer metastasis and TGF-β signaling. Cancer cells alter their morphology through epithelial-mesenchymal transition (EMT) induced by TGF-β signaling pathway activity, increasing their migratory potential. Invading the basement membrane and the extracellular matrix, tumor cells reach the vasculature (blood or lymph vessels) and become circulating tumor cells (CTCs) after intravasation. Gradually, the magnitudes of TGF-β signaling increase dramatically to enable the EMT-invasion processes. Cancer cells reach a secondary site after extravasation. Following TGF-β signaling reduction and consequent mesenchymal-epithelial transition (MET), cancer cells colonization proceeds to the growth of a metastatic lesion. Anti-TGF-β therapies administered in early stage cancers, before initial invasion, would inhibit metastasis by avoiding EMT. The same strategies used to treat late-stage cancers would also induce MET and seeding of secondary tumors.](fcell-08-00605-g001){#F1}

Different molecular pathways are associated with the phenotypic changes observed in metastatic cells, including those mediated by transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), hepatocyte growth factor (HFG), platelet derived growth factor (PDGF), notch, and wnt ([@B78]). Among these important pathways, TGF-β signaling is considered to act as a master inducer of EMT, invasion and metastasis by controlling different genes and proteins related to cytoskeleton assembly ([@B42]), cell-cell attachment ([@B58]) and ECM remodeling ([@B73]). TGF-β is a secreted dimeric polypeptide that elicits cellular effects via cell surface TGF-β type I and type II receptors (TβRI and TβRII). They have intrinsic serine/threonine kinase activity and activate intracellular (non)SMAD signaling pathways ([@B49]). Each step in the TGF-β signaling pathway is tightly regulated, and subject to crosstalk with other signaling pathways ([@B65]). TGF-β signaling pathway is well-characterized and many strategies have been used to interfere with its activity ([@B22]). Nevertheless, even if the selective inhibition of TGF-β bioavailability, TGF-β/TGF-β receptor interaction or TGF-β receptor kinase activity is efficacious *in vitro* and *in vivo*, outcomes observed for anti-TGF-β therapies in clinical settings are often unsatisfactory. In the next sections, we provide a brief overview of TGF-β signaling pathways (section "TGF-β as a Critical Driver in Cancer Progression"); describe and compare different TGF-β signaling inhibitors used *in vitro*, *in vivo*, and in human patients (section "Anti-TGF-β Therapies and Their Poor Outcomes in Cancer Clinical Trials"); and discuss critical issues in preclinical experiments that so far have been largely ignored/overlooked that could explain the poor outcomes observed in cancer clinical trials (sections "Controlling Metastasis Critical Steps: The Dual Role of TGF-β," "TGF-β Dynamic Signaling," "Tumor Microenvironment Regulates TGF-β Signaling," and "Exosomes as a Mechanism of TGF-β Secretion and Signaling Amplification"). When used in particular studies, TGF-β isoforms are indicated during this discussion, otherwise they are referred as TGF-β if this specificity is not relevant.

TGF-β as a Critical Driver in Cancer Progression {#S2}
================================================

Until early 1980s, thanks to studies exploring the role of infectious agents on cancer development, the acquisition of a malignant phenotype was greatly associated with a virus-induced reprogramming of normal cells ([@B97]; [@B60]). Products of avian, murine and feline tumor viruses' genomes were shown to drive the malignant transformation of normal cells by the hyperactivation of signaling pathways ([@B106]; [@B60]; [@B46]). In this scenario, the elevated secretion of growth factors was described as an important mechanism able to cause normal fibroblasts transformation, as observed by an increased anchorage-independent growth potential *in vitro* that was intimately associated with cancer cells behavior *in vivo* ([@B25]). These molecules later named as transforming growth factors (TGF) were later purified and assigned as TGF-α and TGF-β, being the later characterized as a critical component in the process of malignant transformation ([@B85], [@B84]; [@B4]). Since then, many other related molecules were studied and nowadays TGF-β is part of a protein family of growth factors and cytokines.

Based on similarity in sequence and function, TGF-β family is divided in two subgroups: TGF-βs, activins, and nodals forming one group and bone morphogenetic proteins (BMP)s and anti-muellerian hormone the other. The cellular responses to TGF-β and BMP are highly context-dependent, and have been attributed both anti- and pro-tumorigenic roles in different cancer types and/or stages of cancer progression ([@B13]; [@B124]; [@B68]; [@B88]; [@B108]). The biphasic role of TGF-β family pathways in cancer were already reviewed in details by others ([@B59]; [@B92]). Among all TGF-β family members, the targeting of TGF-β pathway has been explored most for therapeutic gain in the treatment of cancer patients ([@B22]; [@B49]). In this review, therefore, we focus on the TGF-β signaling pathway and selective intervention strategies as a background to discuss problems related to pharmacological inhibitors for TGF-β family members used in preclinical and clinical cancer studies.

TGF-β Secretion and Activation {#S2.SS1}
------------------------------

The expression TGF-β isoforms (TGF-β1-3) is coordinated in tissues according to physiopathological conditions ([@B98]; [@B23]; [@B26]; [@B45]). Importantly, TGF-β is secreted in an inactive form in which the N-terminal sequence (also termed latency-associated peptide, LAP), and a C-terminal sequence (active cytokine) are non-covalently linked ([@B109]). Dimers of TGF-β:LAP associate with the latent TGF-β binding protein (LTBP) to form the large latent complex (LLC) ([@B101]; [@B109]). While LAP prevents TGF-β activation, LTBP promotes secretion and can mediate the TGF-β association with proteins in ECM. Besides enzymatic cleavage, a non-enzymatic mechanism of TGF-β activation is also reported and relies on the interaction of LLC with integrins. In cells with enhanced contractility, the tension created by cytoskeleton exerts physical forces that unfold LAP and release active TGF-β ([@B101]; [@B93]).

TGF-β Receptor Signaling Pathways {#S2.SS2}
---------------------------------

After secretion and activation, TGF-β ligands bind to heteromeric complexes of type I and type II serine/threonine kinase receptors (i.e., TβRI and TβRII). TβRII is a constitutive active kinase that phosphorylates TβRI upon ligand binding, thereby enabling the transduction of extracellular signal into the cell ([@B127]). The activated TβRI initiates intracellular signaling by phosphorylation of downstream effector molecules. Besides TβRI and TβRII, TGF-β can interact with more abundant auxiliary receptors, e.g., TGF-β type III receptor (TβRIII), that lack an enzymatic intracellular motif ([@B3]; [@B98]). These co-receptors can enable presentation of TGF-β to TβRI and TβRII and thereby regulate cellular responsiveness ([@B67]; [@B98]). Moreover, as TGF-β isoforms bind with different affinity to co-receptors, they contribute to isoform specific responsiveness to different cell types ([@B3]; [@B51]).

SMADs act as specific effectors downstream of activated TGF-β family type receptors. In the canonical TGF-β-SMAD signaling pathway ([Figure 2](#F2){ref-type="fig"}), TβRI kinase induces the phosphorylation of a Sma- and Mad- related (SMAD) 2 and 3. BMP type I receptors mediate the phosphorylation of distinct set of R-SMADs, i.e., SMAD1, 5, and 8. Common SMAD (Co-SMAD), i.e., SMAD4 binds to phosphorylated R-SMADs to form heteromeric complexes that accumulate in the nucleus and control target gene expression. Another set of SMADs are the inhibitory SMADS (I-SMADs), i.e., SMAD6 and 7. I-SMADs antagonize signal transducing SMADs via multiple mechanisms, including direct competition with R-SMADs for SMAD4, and recruitment of ubiquitin ligases that drive type I receptor polyubiquitination and degradation. Besides canonical SMAD signaling, TGF-β family type I receptors can also initiate so-called non-SMAD signaling pathways that follow intracellular downstream routes, controlling the stability, activity and expression of genes and proteins ([@B76]; [@B94]; [@B51]; [@B123]; [@B35]). Different studies have demonstrated for example the TβRI-induced activation of mitogen-activated protein kinase (MAPK) ([@B103]), and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB/AKT) pathways ([@B54]).

![Canonical TGF-β signaling pathway and TGF-β signaling targeting therapies. After TGF-β mRNA translation (step I) and secretion, the large latent complex (LLC) composed of TGF-β, latency associated peptide (LAP), and latent TGF-β binding protein (LTBP) is deposited to the extracellular matrix (ECM). The interaction between LTBP and integrins increases TGF-β:LAP dissociation and TGF-β activation (step II). TGF-β binding to surface receptors (step III) is followed by TβRII-mediated TβRI transphosphorylation (step IV). The signaling is then transduced to cytosol by TβRI-induced phosphorylation of SMAD2 and 3 (step V), followed by their association with SMAD4, accumulation in the nucleus and regulation of target genes transcription. Anti-TGF-β therapies target critical steps in order to impair TGF-β signaling. Antisense oligonucleotides (ASOs) prevent the translation of TGF-β mRNA (step I). Anti-integrins prevent TGF-β activation (step II). Ligand traps avoid cytokine binding to its receptors (step III). TβRII and TβRI kinase inhibitors block type II-mediated type I receptor phosphorylation (step IV) and type I-mediated SMAD2 and 3 phosphorylation (step V), respectively.](fcell-08-00605-g002){#F2}

By activating its canonical and non-canonical pathways, TGF-β controls multiple processes in cell homeostasis. In non-malignant cells and in early stage cancers, TGF-β exerts a tumor-suppressive role inducing cell cycle arrest and apoptosis. In fact, inactivating mutations in TGF-β receptors and SMADs are frequently observed in cancers (e.g., colorectal, pancreas, and lung cancers) ([@B47]; [@B24]; [@B94]; [@B121]; [@B13]; [@B35]). Nonetheless, many other cancer types, such as brain, breast and skin, bypassing TGF-β cytostatic or pro-apoptotic effects through mutations in different pathways (e.g., PI3K/AKT), become invasive by subverting TGF-β activity to their own benefit ([@B14]; [@B115]). In this scenario, TGF-β tumor-promoter role contributes directly and indirectly with metastatic potential of cancer cells. Directly, TGF-β induces EMT to support migration and invasion of cancer cells as previously mentioned. Indirectly, TGF-β acts on distinct elements of tumor microenvironment, suppressing immune surveillance, promoting angiogenesis and activating cancer-associated fibroblasts that will further contribute to metastasis ([@B50]; [@B63], [@B64]; [@B99]).

The accumulated evidences about critical steps in TGF-β signaling activation combined to the relevance of TGF-β in cancer progression led to the development of multiple strategies to abrogate its activity. Anti-TGF-β therapies have been extensively investigated, but despite their very well-established efficacies and ability to act on target, clinical trials are still unable to reproduce these outstanding results obtained *in vitro* and *in vivo* ([@B1]). On the next section we present different mechanisms to block the TGF-β signaling pathway and a brief compilation of preclinical and clinical data obtained from studies using TGF-β inhibitors in order to contextualize the missing points when these therapies are translated from bench-to-bedside.

Anti-TGF-β Therapies and Their Poor Outcomes in Cancer Clinical Trials {#S3}
======================================================================

Multiple strategies have been developed to target the TGF-β signaling pathway, including interference with activation of latent TGF-β, ligand-receptor interactions, and receptor kinase inhibitors. While *in vitro* and preclinical models have been clearly successful, so far the outcomes from clinical trials to treat different types of cancers have frequently shown (at best) only a minor survival benefit and even sometimes adverse effects. One reason for poor clinical translation may well be that the preclinical data may suffer from publication bias for positive results, and that the animal models used in these studies poorly reflect the cancers developed in patient. In addition, with TGF-β being a multifunctional cytokine of key importance to the maintenance of tissue homeostasis, targeting of TGF-β signaling has been associated with on-target cardiovascular toxic side effects and formation of benign tumors ([@B22]). Inappropriate patient selection in clinical trials may also contribute to the inability to demonstrate favorable survival benefit. Moreover, as targeting TGF-β will not kill the cancer cell, but is aimed at inhibiting invasion and metastasis, it will have to be used with other agents that do kill cancer cells ([@B10]; [@B126]). Furthermore, targeting TGF-β signaling has been frequently aimed at inhibiting cancer cell invasion and metastasis, but inhibition of immune evasion by blocking the potent immune suppressive function of TGF-β might actually be more important for anti-cancer activity of TGF-β targeting agents ([@B40]; [@B116]; [@B86]; [@B114]; [@B11]). Thus, drugs used so far do not recapitulate preclinical data and the outcomes reported for these tests are inconsistent among patients as discussed in the following sections. In order to understand the mechanisms of action on which these strategies are based and the possible reasons for their failure in clinical tests, four categories of anti-TGF-β therapies will be further discussed: (i) antisense oligonucleotides (ASOs), (ii) anti-integrins, (iii) ligand traps, and (iv) kinase inhibitors ([Figure 2](#F2){ref-type="fig"}).

Antisense Oligonucleotides {#S3.SS1}
--------------------------

ASOs are designed to bind to and prevent TGF-β mRNA translation, consequently decreasing its expression. Tests in mesothelioma and prostate cancer cells lines, for example, demonstrated its effectiveness in dramatically reducing TGF-β protein expression and inhibiting anchorage-independent growth ([@B33]; [@B71]). Further experiments *in vivo* showed reduced tumor growth in animals subjected to ASOs treatments and these results were associated with impairment of TGF-β-mediated immune suppression ([@B33]; [@B71]).

Based on its proven specificity observed in preclinical models, ASOs have progressed to clinical trials. AP 12009 (or Trabedersen), an ASO targeting TGF-β2 mRNA, was used to treat multiple cancer types. The safety of Trabedersen was demonstrated in phase I trials in patients with pancreas, colon, and skin cancers (NCT00844064). In a phase II trial, Trabedersen was administered to patients with glioblastoma and anaplastic astrocytoma (NCT00431561), achieving a particularly interesting outcome: compared to patients treated with standard chemotherapy (i.e., Temozolomide or Procarbazine/Lomustine/Vincristine), patients submitted to this ASO appeared to exhibit an improvement in cognitive functions. Nevertheless, the same study failed to demonstrate increased antitumor responses in patients treated with Trabedersen compared to patients treated with standard chemotherapy. Finally, the only phase III clinical trial using Trabedersen, also to treat brain cancer patients (NCT00761280), has been terminated by its inability to recruit the projected number of patients and only descriptive analyses are available. [Table 1](#T1){ref-type="table"} summarizes main results obtained in cancer clinical trials using ASOs.

###### 

Overview of anti-TGF-β therapies based on antisense oligonucleotides used in cancer clinical trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (Target)       Clinical trial (Phase)    Status       Cancer type                                     Patients enrolled   Arms                                                       Outcomes
  ------------------- ------------------------- ------------ ----------------------------------------------- ------------------- ---------------------------------------------------------- ---------------------------------------------------------------------
  AP 12009 (TGF-β2)   NCT00431561 (Phase II)    Completed    Glioblastoma and anaplastic astrocytoma         141                 AP 12009 (10 μM)\                                          Improved PFS\
                                                                                                                                 AP 12009 (80 μM)\                                          Improved OS\
                                                                                                                                 Temozolomide or procarbazine, lomustine, and vincristine   (Results for responders regardless drug concentration administered)

  AP 12009 (TGF-β2)   NCT00761280 (Phase III)   Terminated   Glioblastoma and anaplastic astrocytoma         27                  AP 12009 (10 μM)\                                          NA
                                                                                                                                 Temozolomide or carmustine or lomustine                    

  AP 12009 (TGF-β2)   NCT00844064 (Phase I)     Completed    Melanoma, pancreatic and colorectal neoplasms   62                  Single-arm: AP 12009 (dose escalation)                     NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PFS, progression-free survival; OS, overall survival. NA, not available.

Anti-integrins {#S3.SS2}
--------------

TGF-β activation by dissociation from LAP is a crucial step that precedes its binding to TβRI/II. As mentioned previously, different mechanisms work toward TGF-β activation, binding of LTBP to integrins is considered one of them to greatly improve the activation process. In fact, integrins expression is associated with elevated availability of activated TGF-β and consequent increase of EMT, migration and invasion *in vitro* for many cancer cell lines ([@B87]; [@B72]; [@B30]; [@B102]). Furthermore, the activation of TGF-β signaling pathway is shown to induce integrins expression leading to a positive feedback ([@B73]; [@B66]; [@B107]). Consequently, many strategies targeting TGF-β signaling by blocking integrin-mediated TGF-β activation were developed and tested in preclinical models. For instance, antibodies blocking integrins (e.g., 10D5 and 264RAD) efficiently impair the growth of primary and secondary tumors in models of breast and prostate cancers, though the effects exerted by these therapies could also be related to reduced TGF-β-mediated immunosuppression and angiogenesis ([@B72]; [@B30]).

Seven cancer clinical trials exploring the effects of integrins inhibitors were conducted so far, but two were terminated (NCT01122888 and NCT02337309) before prematurely conclusion and three others do not present results publicly available (NCT00721669, NCT00284817, NCT00635193). The two remaining studies evaluated the use of EMD 121974 (or Cilengitide), an antibody targeting integrins αvβ3 and αvβ5, to treat patients with head and neck squamous cell carcinoma (phases I and II, NCT00705016) and glioblastoma (phase III, NCT00689221). Unfortunately, both trials report that administration of Cilengitide did not result in improved antitumor activity or increased overall survival compared with standard chemotherapies. [Table 2](#T2){ref-type="table"} shows an overview of clinical studies that evaluated integrin inhibitors to treat cancer patients.

###### 

Overview of anti-TGF-β therapies based on integrin inhibitors used in cancer clinical trials.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (Target)                           Clinical trial (Phase)      Status       Cancer type                                                                                                                       Patients enrolled   Arms                                                                 Outcomes
  --------------------------------------- --------------------------- ------------ --------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------------------------------------------------------- ------------------------
  EMD 121974 (Integrins αvβ3 and αvβ5)    NCT01122888 (Phase I)       Terminated   Adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult solid neoplasms and recurrent adult brain neoplasms   41                  Sunitinib + EMD 121974\                                              NA
                                                                                                                                                                                                                                         Sunitinib                                                            

  EMD 121974 (Integrins αvβ3 and αvβ5)    NCT00705016 (Phases I/II)   Completed    Head and NeckSquamous Cell Carcinoma                                                                                              184                 Cilengitide (2000 mg) once weekly + cetuximab + 5-FU + cisplatin\    No improvement in PFS\
                                                                                                                                                                                                                                         Cilengitide (2000 mg) twice weekly + cetuximab + 5-FU + cisplatin\   No improvement in OS
                                                                                                                                                                                                                                         Cetuximab + 5-FU + Cisplatin                                         

  EMD 121974 (Integrins αvβ3 and αvβ5)    NCT00689221 (Phase III)     Completed    Glioblastoma                                                                                                                      545                 Cilengitide + temozolomide + radiotherapy\                           No improvement in PFS\
                                                                                                                                                                                                                                         Temozolomide + radiotherapy                                          No improvement in OS

  SF1126 (Integrin-targeted PI3 kinase)   NCT02337309 (Phase I)       Terminated   Neuroblastoma                                                                                                                     4                   Single-arm: SF1126                                                   NA

  IMGN388 (Integrins αv)                  NCT00721669 (Phase I)       Completed    Melanoma, breast carcinomas, lung carcinomas and ovary carcinomas                                                                 60                  Single-arm: IMGN388                                                  NA

  MEDI-522 (Integrin αvβ3)                NCT00284817 (Phases I/II)   Completed    Colorectal cancer                                                                                                                 17                  MEDI-522 (D0: 4 mg/kg; W1--W51: 1 mg/kg)\                            NA
                                                                                                                                                                                                                                         MEDI-522 (D0: 4 mg/kg; W1--W51: 2 mg/kg)\                            
                                                                                                                                                                                                                                         MEDI-522 (D0: 6 mg/kg; W1--W51: 2 mg/kg)\                            
                                                                                                                                                                                                                                         MEDI-522 (D0: 6 mg/kg; W1--W51: 3 mg/kg)                             

  M200 (Integrin α5β1)                    NCT00635193 (Phases I/II)   Completed    Ovarian cancer and primary peritoneal cancer                                                                                      138                 Liposomal doxorubicin (40 mg/m^2^) + M200 (7.5 mg/kg)\               NA
                                                                                                                                                                                                                                         Liposomal doxorubicin (40 mg/m^2^) + M200 (15.0 mg/kg)\              
                                                                                                                                                                                                                                         Liposomal doxorubicin (40 mg/m^2^)                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-FU, 5-fluoracil; D0, First day of treatment; W1--W51, weeks 1--51 of treatment; PFS, progression-free survival; OS, overall survival; NA, not available.

Interfering With Ligand-Receptor Interactions {#S3.SS3}
---------------------------------------------

TGF-β signals when the active cytokine binds to surface receptors that will further transduce the signal to cytoplasm and two main strategies were developed so far as ligand trap to prevent this step: (i) administration of antibodies against ligand or its receptors, and (ii) the use of soluble TGF-β receptors (sRII or sRIII) or receptors fused to immunoglobulins (TβRII:Fc) as ligand sequesters. Many molecules designed as ligand traps have been characterized *in vitro* and *in vivo.* Their ability to reduce the availability of the active cytokine, diminish SMAD2/3 phosphorylation and decrease the expression of TGF-β target genes, support their on-target activity ([@B36]). For instance, treatments with 1D11 or 2G7 (monoclonal anti-TGF-β antibodies) were shown to reduce the metastatic burden and angiogenesis in breast cancer models and further experiments associated these results to an increased cytotoxicity exhibited by natural killer (NK) cells ([@B5]; [@B36]; [@B12]). Similar results were obtained by employing antibodies raised against the extracellular domain of TGF-β receptors (particularly against TβRII), reducing the growth of primary and secondary tumors as well as increasing the numbers of NK and cytotoxic T cells ([@B124]). Also, mice models treated with the sRIII ([@B9]) or TβRII:Fc ([@B74]; [@B118]) showed a reduced number of metastases in different organs analyzed (i.e., lung, liver, and pancreas). This approach has recently been expanded by fusing the extracellular domain of TβRII with an anti-programmed cell death ligand-1 (PD-L1) antibody to obtain a bifunctional therapy and circumvent the immunosuppression commonly observed in solid tumors. *In vitro*, this bifunctional therapy (M7824) was demonstrated to increase the lysis of urothelial carcinoma cells by T cells compared to effects of anti-PD-L1, a result that was associated to the upregulation of molecules involved in immunogenic modulation (i.e., intercellular adhesion molecule 1/ICAM-1, carcinoembryonic antigen/CEA, and Fas cell surface death receptor/FAS) ([@B43]). A similar pattern has also been demonstrated for this strategy *in vivo*, in which the administration of an anti-PD-L1-TβRII reduced tumor burden and promoted activation of CD8^+^ T lymphocytes and NK cells in breast and colorectal cancer models ([@B82]).

Multiple observations in preclinical models led ligand traps to cancer clinical trials, but different from animal models, results in humans have been inconsistent. The TGF-β sequester GC1008 (also known as Fresolimumab), one of the best characterized monoclonal anti-TGF-β1-3 antibodies was used in patients with renal cell carcinoma (phase I, NCT00923169), melanoma (phases I and II, NCT00923169), glioma (phase II, NCT01472731), mesothelioma (phase II, NCT01112293), and breast cancer (phase II, NCT01401062). Even though a relationship between safety and antitumor activity was shown, it was also observed a decreased expression of activating surface proteins in NK cells (i.e., CD226 and CD244) which could impair therapy effects and partially explain why most patients treated in these studies did not present improved overall survival. Currently two other clinical trials using anti-TGF-β antibodies are recruiting: a phase I/Ib trial (NCT02947165) using NIS793 (anti-TGF-β) to evaluate its safety and tolerability as a single agent or in combination with PDR001 (anti-programmed cell death-1, or PD-1), and another phase I study (NCT03192345) using SAR439459 (anti-TGF-β) to evaluate safety, pharmacokinetics, pharmacodynamics and antitumor activity as a monotherapy or in combination with Cemiplimab (anti-PD-1) in multiple cancers. Similar to antibodies targeting the ligand, many problems were also observed when using anti-TGF-β receptors antibodies. For example, a study evaluating the safety of LY3022859 (anti-TβRII) to treat solid tumors (NCT01646203) failed in establishing its maximum tolerated dose, restricting its usage in other phases. Finally, the only clinical trial (phase I) proposed so far to treat cancer patients by blocking TGF-β signaling pathway by the use of soluble TGF-β receptors is still recruiting patients. This study (NCT03834662) will evaluate AVID200 safety, tolerability, and dose-limiting toxicities in advanced or metastatic solid cancers. Results obtained in clinical trials evaluating the interference between ligand-receptor interactions in the treatment of cancer patients are summarized in [Table 3](#T3){ref-type="table"}.

###### 

Overview of anti-TGF-β therapies based on the interference between ligand-receptor interactions used in cancer clinical trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (target)                           Clinical trial (phase)   Status       Cancer type                                                              Patients enrolled   Arms                                            Outcomes
  --------------------------------------- ------------------------ ------------ ------------------------------------------------------------------------ ------------------- ----------------------------------------------- ------------------------------------
  GC1008 (TGF-β1 and TGF-β2)              NCT00923169 (Phase I)    Completed    Renal cell carcinoma and melanoma                                        22                  GC1008 (10 mg/kg)\                              Highest safe dose: 15 mg/kg
                                                                                                                                                                             GC1008 (15 mg/kg)                               

  GC1008 (TGF-β1 and TGF-β2)              NCT01472731 (Phase II)   Completed    Glioma                                                                   12                  Bioimaging with 89Zr-GC1008 (37 MBq total)\     NA
                                                                                                                                                                             Treatment with GC1008 (5 mg/kg)                 

  GC1008 (TGF-β1 and TGF-β2)              NCT01112293 (Phase II)   Completed    Mesothelioma                                                             14                  Single-arm:GC1008 (3 cycles)                    NA

  GC1008 (TGF-β1 and TGF-β2)              NCT01401062 (Phase II)   Completed    Metastatic breast cancer                                                 23                  GC1008 (1 mg/kg) + radiotherapy\                No improvement in abscopal effect\
                                                                                                                                                                             GC1008 (10 mg/kg) + radiotherapy                Improved OS in arm II

  NIS793 (TGF-β)                          NCT02947165 (Phase I)    Recruiting   Breast, lung, hepatocellular, colorectal, pancreatic and renal cancers   220                 NIS793\                                         NA
                                                                                                                                                                             NIS793 + PDR001                                 

  SAR439459 (TGF-β1, TGF-β2 and TGF-β3)   NCT03192345 (Phase I)    Recruiting   Advanced solid tumors                                                    225                 SAR439459 (dose escalation)\                    NA
                                                                                                                                                                             SAR439459 (dose expansion)\                     
                                                                                                                                                                             SAR439459 (dose escalation) + cemiplimab\       
                                                                                                                                                                             SAR439459 (dose expansion) + cemiplimab         

  LY3022859 (TβRII)                       NCT01646203 (Phase I)    Completed    Advanced solid tumors                                                    14                  IMC-TR1 (1.25 mg/kg)\                           DLT reported\
                                                                                                                                                                             IMC-TR1 (dose escalation -- 12.5 to 1600 mg)\   TEAE reported\
                                                                                                                                                                             IMC-TR1 (dose escalation -- 800 to 1600 mg)     SAE reported

  AVID200 (TGF-β1 and TGF-β3)             NCT03834662 (Phase I)    Recruiting   Malignant solid tumors                                                   36                  AVID200 (180 mg/m^2^)\                          NA
                                                                                                                                                                             AVID200 (550 mg/m^2^)\                          
                                                                                                                                                                             AVID200 (1100 mg/m^2^)                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS, overall survival; DLT, dose-limiting toxicity; TEAE, treatment emergent adverse events; SAE, serious adverse event; NA, not available.

Kinase Inhibitors {#S3.SS4}
-----------------

Kinase inhibitors block the binding of ATP to TGF-β receptors, reducing their kinase activity and limiting downstream signaling transduction. Similar to ligand traps, their ability to specifically target and impair TGF-β signaling pathway activation has been demonstrated by using cancer cells derived from different tumors (e.g., brain, breast, pancreas, and mesothelium). Acting exclusively on TβRI or interfering with type I and II TGF-β receptors, these inhibitors were shown to reduce tumor growth, metastasis, recurrence and angiogenesis in mouse models ([@B39]; [@B100]; [@B81]; [@B122]).

Given the outstanding results achieved *in vitro* and *in vivo*, kinase inhibitors were also investigated in clinical studies. LY2157299 (or Galunisertib) had its safety demonstrated in a phase I trial with glioblastoma patients (NCT01220271), but the antitumor response was only achieved in 3 of 28 patients. Still, 10 other studies are currently in development or recruiting patients with different types of cancer in advanced stage. LY3200882 is the most recent TGF-β inhibitor in this class and clinical studies (phases I and II) intend to recruit patients to evaluate safety and antitumor activity as single agent or in combination with other chemotherapies (NCT02937272, NCT04031872). [Table 4](#T4){ref-type="table"} presents an overview of cancer clinical trials using kinase inhibitors.

###### 

Overview of anti-TGF-β therapies based on kinase inhibitors used in cancer clinical trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug (target)      Clinical trial (phase)      Status                   Cancer type                    Patients enrolled   Arms                                                          Outcomes
  ------------------ --------------------------- ------------------------ ------------------------------ ------------------- ------------------------------------------------------------- ----------
  LY2157299 (TβRI)   NCT01220271 (Phases I/II)   Completed                Glioma                         75                  Phase I\                                                      NA
                                                                                                                             LY2157299 (160 mg) + radiotherapy + temozolamide\             
                                                                                                                             LY2157299 (300 mg) + radiotherapy + temozolamide\             
                                                                                                                             Phase II\                                                     
                                                                                                                             LY2157299 (established dose) + radiotherapy + temozolamide\   
                                                                                                                             Radiotherapy + temozolamide                                   

  LY3200882 (TβRI)   NCT02937272 (Phase I)       Active, not recruiting   Solid tumors                   223                 LY3200882\                                                    NA
                                                                                                                             LY3200882 + LY3300054\                                        
                                                                                                                             LY3200882 + gemcitabine + nab-paclitaxel\                     
                                                                                                                             LY3200882 + cisplatin + radiation                             

  LY3200882 (TβRI)   NCT04031872 (Phases I/II)   Active, not recruiting   Colorectal metastatic cancer   31                  Single-arm: LY3200882 + capecitabine                          NA
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cmax, maximum concentration; ORR, objective response rate; PFS, progression-free survival; CBR, clinical benefit rate; CR, complete response; PR, partial response; AUC, area under the curve; SAE, serious adverse event; OS, overall survival; NA, not available.

As described above, positive results in clinical tests using anti-TGF-β therapies were observed, but they are not common to all patients. Even when interesting outcomes were achieved, they are not satisfactorily distinct from those results reported for current therapies, as would be expected by data obtained *in vitro* and *in vivo*. This highlights a major problem: a gap in the current comprehension about TGF-β activity during cancer progression in human patients. Based on the most recent findings, we argue in next section that important points about TGF-β signaling have or are not being properly considered in preclinical studies. Specifically, we address (i) the dual role of TGF-β signaling in EMT and MET; (ii) TGF-β dynamic signaling; (iii) the functional difference of TGF-β secreted by exosomes; and (iv) the regulatory effects of tumor microenvironment (TME) -- particularly by cancer-associated fibroblasts -- on TGF-β signaling activities and its functions.

Controlling Metastasis Critical Steps: the Dual Role of TGF-β {#S4}
=============================================================

The critical role of TGF-β on EMT, increasing cancer cells migration and invasion *in vitro* ([@B49]) have been comprehensively established. By using pharmacological inhibitors studies have also demonstrated convincingly that blocking TGF-β signaling represents an effective strategy to impair metastasis *in vivo* ([@B71]; [@B124]; [@B12]; [@B30]). Still, few studies consider that TGF-β can exert an important anti-MET activity, avoiding a critical late-stage step in metastasis ([Figure 1](#F1){ref-type="fig"}). Also, cancer patients and animal models differ in a very important point that could be critical to classify TGF-β as friend or foe: the timing at which the treatment is administered.

It is usual to start anti-TGF-β treatment in animal models as soon as the cancer reaches a palpable volume or even earlier. By treating cancer at such an early stage, researchers avoid that malignant cells invade surrounding tissues and progress to vasculature intravasation, inhibiting metastasis and reinforcing the dangerous role of TGF-β in metastasis. Nevertheless, cancers in humans are not always diagnosed at early stages because it takes time until the initial symptoms appear, not mentioning that the TGF-β targeting treatments were often for very late stage cancer patients. Thus, when diagnosis occurs, many tumor cells have already spread and are found in the blood and/or lymph. These CTCs and possible undetectable micrometastases underwent EMT before treatment has started. Therefore, administering anti-TGF-β therapies by this time could block one of the most important molecular pathways that sustain cancer cells mesenchymal phenotype, inducing MET and facilitating the growth of secondary tumors ([Figure 1](#F1){ref-type="fig"}).

Based on their enhanced invasive potential, cancer cells with mesenchymal phenotype usually result in more metastasis than counterparts with epithelial phenotype when implanted in solid tissues. Nevertheless, to represent the CTCs usually observed in cancer patients, these cells should be evaluated after they reach the bloodstream. Indeed, the reduced ability of mesenchymal cells to colonize secondary organs and establish distant metastasis has been described for many cancer types in animal models. In a striking report [@B14] describe that blocking TGF-β activity resulted in different outcomes when employing cancer cells with distinct initial phenotypes. In this study, researchers used a TβRI kinase inhibitor to treat breast cancer cells carrying mesenchymal -- or epithelial-like phenotypes. After intracardiac inoculation, epithelial-like cancer cells treated or not with anti-TGF-β metastasized at the same rate, while mesenchymal-like cancer cells responded to TGF-β signaling pathway block by slight increasing the number of lung metastases. By disrupting TGF-β signaling, researchers probably induced MET in these cancer cells, given them more benefits than disadvantages in secondary organ colonization.

Thus, the generally not considered role of TGF-β in promoting anti-MET could actually make this cytokine an interesting friend to block cancer metastasis in advanced tumors that already started to spread. In addition, this potential TGF-β function highlights the relevance of clearly determining which patients should be submitted to TGF-β inhibitors and considering probable poor outcomes for post-operative patients or patients with cancer in advanced stage ([Figure 1](#F1){ref-type="fig"}). A thorough understanding of detailed and exacting roles played by TGF-β at specific cellular stages of cancer metastasis is in urgent need in order to devise an effective, precise anti-TGF-β treatment regimen.

TGF-β Dynamic Signaling {#S5}
=======================

How treatment schemes for anti-TGF-β therapies are defined? Do these protocols consider natural fluctuations in TGF-β signaling? Similar to observations in many other molecular pathways, TGF-β signaling is also controlled by negative feedbacks, being SMAD7 its best characterized feedback inhibitor. In a simplified model, high levels of stimulus (TGF-β activity) result in increased *SMAD7* expression and TGF-β/SMAD signaling inhibition (SMAD7 activity) that in turn disrupt the initial stimulus ([@B76]; [@B52]; [@B123]; [@B55], [@B56]). Therefore, careless administration of TGF-β inhibitors should be expected to result in rapid decrease of TGF-β activity, followed by its pronounced increase when TGF-β receptors are thereafter activated.

Other than proteins, miRNA and lncRNA targeting TGF-β, its receptors or downstream effectors ([@B49]), TGF-β signaling is also opposed by BMP signaling -- commonly associated to a MET-promoter effect -- in many metastatic cancers ([@B38]; [@B53]; [@B108]). Considering this antagonism, TGF-β pharmacological targeting should increase BMP activity, preventing cancer cell invasion and reducing the risk of metastasis. Nevertheless, two different problems could arise from that strategy. First, as discussed in the previous section, by promoting MET in cancer cells after intravasation/extravasation, BMP signaling pathway would actually contribute to metastatic development. Second, it is not unusual to detect alterations in BMP pathway, being these effects imposed by malignant cells and other elements at the TME. Gremlin 1 (GREM1) is a BMP antagonist that binds to the ligand, preventing its interaction with membrane receptors and activation of downstream signaling pathway. As recently demonstrated by [@B83] elevated levels of GREM1 correlate with a poor prognostic for breast cancer patients. Also, the same study showed that GREM1 promotes EMT and invasion of breast cancer cells *in vitro* and it is correlated with higher levels of intravasation and extravasation in a zebrafish model.

Therefore, considering the existence of TGF-β regulatory components, oscillations in TGF-β signaling pathway were mathematically modeled *in silico* and tested *in vitro*. Many groups demonstrated that dynamic changes occur, including fluctuations in levels of SMADs phosphorylation and activity ([@B128]; [@B113]), differential nuclear-cytoplasmic shuttling ([@B41]; [@B111]) and irregular regulatory effects on gene transcription ([@B41]; [@B128]; [@B113]). These alterations are natural results of intracellular homeostasis, but these effects can also be induced by exposure to different ligand concentrations over time ([@B91]; [@B111]; [@B113]; [@B110]). It is reasonable to assume that metastatic cells traveling through different tissues on their way to distant organs are not submitted to a homogeneous environment. Otherwise, malignant cells are likely to be subjected to other cell types with heterogeneous TGF-β secretion potentials, what is not commonly reproduced *in vitro* and could result in different states of cancer cell activation. [@B95] studying the influence of this cytokine on the development of *Xenopus* embryos showed that a pulsed stimulus is more effective than a constant elevation in TGF-β concentrations to promote signaling activation. Moreover, [@B77] analyzing the tumor suppressive role of TGF-β reported that the resistance to TGF-β-induced growth arrest exhibited by some pancreatic cancer cell lines derive from their ability to rapidly export R-SMADs to cytoplasm, while counterparts sensitive to TGF-β retain nuclear SMADs for longer periods.

However, it should not be expected that all cells in a population (i.e., malignant tumor) present similar responsiveness to TGF-β -- or at least not in a synchronized pattern. Evaluating cancer cell migration, [@B68] demonstrated an interesting difference exerted by the dynamics of TGF-β among cells populations *in vitro*. Even though SMAD3 activity was enhanced in migratory cells compared to non-migratory cells, the behavior of migratory cells was uneven. Three subpopulations were classified among these migratory cells, but surprisingly, cells with higher SMAD3 activity moved smaller distances than migratory cells with low or medium SMAD3 activity. Interestingly, this heterogeneous pattern of TGF-β activity in different cells from the same population was also described *in vivo* by [@B41]. Importantly, they demonstrated that TGF-β signaling activity is not sustained during all metastatic steps, and while SMAD2 nuclear localization and SMAD3 activity were detectable in migrating cells, these results were not present in cancer cells in lymph node metastases.

Overall, these results demonstrate that TGF-β signaling is dynamic. Two main mechanisms explain this observation: (i) this molecular pathway is transiently regulated by a negative feedback involving molecules (proteins or RNAs) that present direct interaction with TGF-β or its effectors; and (ii) opposite signaling pathways can inhibit TGF-β signaling for prolonged times and avoid its control on cell phenotype. Understanding how these processes occur in different contexts and reproduce this balance in pre-clinical models will help to establish a better treatment scheme in clinical trials at which anti-TGF-β therapies are carefully administered to prevent amplified TGF-β activation ([Figure 3](#F3){ref-type="fig"}), as such normalizing its signaling.

![TGF-β signaling dynamics change during cancer progression. Late-stage cancer cells present increased intensity and reduced frequency oscillation in TGF-β signaling pathway activity compared to early stage cancer cells.](fcell-08-00605-g003){#F3}

Tumor Microenvironment Regulates TGF-β Signaling {#S6}
================================================

The immunosuppressive role of TGF-β has been explored in many diseases including cancer and the combination of TGF-β inhibitors and immunotherapies is suggested as an alternative to improve the antitumor effect of immune cells. Still, this scenario considers components of TME -- especially immune cells -- as targets rather than sources of TGF-β secretion. It has been demonstrated, for instance, that cells such as myeloid-derived suppressor cells (MDSCs) secrete TGF-β and contribute to cancer progression ([@B116]; [@B11]). Still, other cell types (e.g., endothelial cells and pericytes) already described as important during metastasis could also be involved in this process, but their contribution to carcinogenesis based on TGF-β secretion still not properly explored ([@B34]; [@B69]; [@B22]). Therefore, despite cancer cells, little is known about TGF-β secretion by TME cells.

Considering the interference of cancer-associated fibroblasts (CAFs) in multiple processes during carcinogenesis (e.g., ECM remodeling, angiogenesis, bioenergetics, cancer cells stemness, response to therapies and immune surveillance), their ability to promote TGF-β-mediated EMT, invasion and metastasis started to be evaluated. [@B120] demonstrated that primary breast CAFs-conditioned medium induce EMT markers (e.g., vimentin upregulation and E-cadherin downregulation) in breast cancer cell lines, promoting migration and invasion *in vitro* that could be partially blocked by using an anti-TGF-β antibody or a TβRI kinase inhibitor. Similar results were obtained by [@B75] working with uterine cervical squamous cell carcinoma cells. Surprisingly, they also showed that an exclusive detection of phosphorylated SMAD3 at tumor boundaries were preferentially detected in samples from uterine cancer patients diagnosed with lymph node metastasis, suggesting that the activation of TGF-β signaling pathway in malignant cells is induced by tumor stroma. [@B63], [@B64] using primary fibroblasts isolated from hepatocellular carcinoma patients confirmed the relevance of TME cells signaling on EMT, migration and invasion *in vitro* and metastasis *in vivo* as a result of TGF-β signaling activation.

As discussed before, TGF-β and BMP signaling pathways are commonly describe as opposite molecular pathways, but the consequent effects are not limited to cancer cells. [@B38] showed that lung stromal cells restrict the growth of metastasis by secreting high levels of active BMP. Interestingly, the ability of breast cancer cells to overcome this anti metastatic mechanism was related to secretion of COCO (DAND5) and consequent inhibition of BMP signaling. [@B83], in the same study mentioned before, described that TGF-β-induced CAFs activation results in GREM1 (BMP inhibitor) secretion *in vitro*. This suggestive feed forward loop between CAFs and malignant cells was further reinforced by results showing that GREM1 expression is restricted to tumor stroma in breast cancer patients.

Overall, these data highlight the importance of the microenvironment surrounding cancer cells -- especially CAFs -- secreting or controlling the secretion of TGF-β. Nevertheless, the presence of CAFs in animal models exploring the response to anti-TGF-β therapies is not commonly observed. Thus, together with the points discussed in the previous sections, ignoring the crosstalk between cancer cells and TME components -- especially CAFs -- could hamper the translation of preclinical results to clinical trials using TGF-β signaling pathway inhibitors, explaining the poor and inconsistent outcomes observed in cancer patients ([Figure 4](#F4){ref-type="fig"}), highlighting the need for developing mouse tumor models containing TME or at least CAFs.

![Anti-TGF-β therapies targeting multiple components of tumor microenvironment. Besides epithelial-mesenchymal transition (EMT) in cancer cells, TGF-β secretion at the tumor microenvironment promotes cancer-associated fibroblast (CAF) activation, impaired immune surveillance, pericytes differentiation, and endothelial cell proliferation.](fcell-08-00605-g004){#F4}

Exosomes as a Mechanism of TGF-β Secretion and Signaling Amplification {#S7}
======================================================================

Exosomes are nanosized extracellular vesicles with a diameter ranging from 30 to 100 nm. The role of exosomes on cell communication relies on their ability to transport different types of cargo allowing cell-cell interaction and autocrine or paracrine signaling. Nucleic acids, lipids and many proteins were already described among exosomes cargo, but their specific mechanism of sorting into endosomes still poorly understood ([@B31]; [@B20]; [@B61]). Interestingly, even though TGF-β receptors traditionally localize at the plasma membrane, they present sequences used by cell machinery as signals for internalization ([@B27]; [@B21]). Indeed, it has been shown that these receptors can be directed to early endosomes, activating the SMAD-dependent pathway before being recycled back to the cell surface ([@B27]; [@B21]). Thus, considering the role of endosomes as precursors of exosomes, the secretion of TGF-β by these extracellular vesicles became a suggestive possibility.

In fact, some studies have showed the secretion of exosomal TGF-β by cancer cells and their interaction with other TME components. For instance, [@B86] demonstrated *in vitro* that T cells treated with exosomes derived from breast cancer cell lines exhibit reduced proliferation through a TGF-β-dependent mechanism that could be only partially reverted by treatment with anti-TGF-β antibodies. Furthermore, after show that stage III-IV renal carcinoma patients present higher levels of exosomal TGF-β than patients in stages I-II, [@B114] treated NK cells with tumor-derived exosomes and reported a decrease in their cytotoxicity. Also, using 786-O renal adenocarcinoma cells as a model, the same study demonstrated that TGF-β secreted in exosomes is more efficient to reduce NK cytotoxicity than its free-ligand form. In gastric cancer, [@B119] showed that exosomal TGF-β isolated from peripheral blood is elevated in patients with lymph node metastasis and positively correlates with increased levels of T regulatory lymphocytes.

Reinforcing the role of exosomes in paracrine signaling, [@B112] reported that primary fibroblasts are activated after treatment with exosomal TGF-β secreted by cancer cells. Interestingly, although most TGF-β in these exosomes was present in the latent form, cells stimulated with exosomal TGF-β and TGF-β in its free-ligand form exhibited similar levels of SMAD3 activity. Still, in the opposite direction of this crosstalk, [@B61] demonstrated that CAFs can also secrete exosomal TGF-β. Even more, exosomal TGF-β was show to promote SMAD2/3 phosphorylation in ovarian cancer cells, decreasing their levels of E-cadherin and increasing vimentin expression. As a result of exposure to exosomal TGF-β secreted by CAFs, cancer cells presented enhanced migration and invasion *in vitro* and increased tumor growth *in vivo*.

While studies exploring the mechanisms of carcinogenesis have mostly focused on exosomes as the main type of extracellular vesicles mediating TGF-β transport as cargo, TGF-β secretion in microvesicles/ectosomes have also been reported in other contexts such as in immunology and infectious diseases ([@B16]; [@B89], [@B90]). For instance, [@B16] showed that *Trypanosoma cruzi* infection induces the release of microvesicles (MVs) enriched in TGF-β from blood cells. These MVs associate with the parasite surface, increasing *T. cruzi* invasion into host cells and escape from complement system. Other than that, two studies from Sadallah and collaborators demonstrated that platelet-derived MVs enriched in TGF-β promote immunosuppression by both promoting CD4^+^ T cells differentiation toward a Treg phenotype ([@B89]) and decreasing NK cells activity ([@B89]).

Thus, the extracellular vesicles could work as an alternative mechanism to secrete TGF-β, and particularly in the context of cancer progression, promoting the crosstalk between TME cells and even amplifying TGF-β signaling activation. Furthermore, it is possible that extracellular vesicles prevent the interaction between TGF-β and ligand traps in a mechanism similar to what was shown for exosomes transporting PD-L1 and impairing anti-PD-L1 antibodies activity ([@B80]). Also, the uptaking of extracellular vesicles enriched in TGF-β could activate TGF-β signaling from the cytoplasm. As such, the dynamics of extracellular vesicles trafficking in different cell types likely to influence the extent of downstream effects. As different mechanisms to block exosomes secretion and uptake have been tested *in vitro* ([@B79]; [@B20]), a combinatory approach targeting exosomes and TGF-β signaling simultaneously should be evaluated in order to block both TGF-β forms of secretion -- as a free-ligand and as extracellular vesicles cargo.

Other Perspectives {#S8}
==================

As discussed in the previous sections, anti-TGF-β therapies that successfully inhibit cancer cells EMT, migration, invasion and metastasis in pre-clinical models have faced multiple problems when used to treat cancer patients in clinical trials. However, the combination of these same drugs with immune checkpoint inhibitors has recently emerged as a highly promising approach that can lead to a prolonged anti-cancer response.

The immunosuppressive activity played by TGF-β critically impacts the activity of different immune cell types ([@B117]). More specifically, TGF-β is shown to reduce the proliferation ([@B86]) and activity ([@B105]) of cytotoxic T cells while induces the differentiation of CD4^+^ cells toward a Treg phenotype ([@B19]; [@B40]). Based on this premise, for instance, [@B29] have shown that outcomes obtained with an anti-PD-1 antibody can be improved by combining it with an anti-TGF-β neutralizing antibody treatment in xenograft models of skin cancer. In this study, while the outcome obtained with the anti-PD-1 therapy was limited to a partial regression and correlated with an increased CD4^+^ Treg/CD4^+^ Th cells ratio, a complete tumor regression was achieved by the synergistic response when anti-PD-1 and anti-TGF-β antibodies were combined. Results from [@B96] have corroborated this pattern by demonstrating that the combination of an anti-PD-L1 antibody with a TβRI kinase inhibitor lead to increased survival in the highly immunogenic mouse MC38 colon adenocarcinoma model. Still, because the same combinatorial approach did not lead to similar outcomes in the poorly immunogenic mouse KPC1 pancreatic cancer model, these researches also suggested that combining anti-TGF-β therapies with immune checkpoint inhibitors may be beneficial only for certain types of cancer, highlighting the relevance of an appropriate selection of patients to undergo this therapeutic strategy. In addition, it is noteworthy that the role played by TGF-β in blocking the infiltration of cytotoxic T cells into the cancer mass may not necessarily be induced by cancer cells. In fact, [@B70] and [@B104] demonstrated that the TGF-β-mediated immune exclusion is a response triggered during cancer progression by non-cancer cells from the tumor stroma, particularly by CAFs.

Overall, considering the studies highlighted in this section and the evidences from the use of bifunctional antibodies that simultaneously target TGF-β and PD-1/PD-L1 (as presented in section "Interfering With Ligand-Receptor Interactions." Interfering with ligand-receptor interactions), it is suggestive that the poor outcomes obtained with anti-TGF-β therapies in clinical trials may be improved by their combination with other therapies, particularly with immune checkpoint inhibitors. In this context, experimental studies regarding the immunosuppressive activity played by TGF-β should be expanded and their results compared between "cold tumors" and "hot tumors" in order to obtain a better understanding about the use of TGF-β pharmacological inhibitors to overcome the immune exclusion that is common to different types of cancer. While the use of immune checkpoint inhibitors alone may favor the cytolytic activity of immune cells that are present within the cancer mass, their combination with TGF-β pharmacological inhibitors may increase the infiltration of these cells in "cold tumors." More details about the synergism between TGF-β pharmacological inhibitors and immune checkpoint inhibitors has been reviewed and discussed by others regarding its use in pre-clinical models and clinical trials ([@B37]; [@B7]; [@B44]; [@B62]).

Given the occasional but serious side effect of anti-PD1/PD-L1 therapies on heart ([@B8]) and TGF-β's important role played in heart development and homeostasis ([@B28]; [@B98]; [@B2]), the challenges for the combined or bifunctional antibody therapies are to minimize the potential fatal side effect.

Concluding Remarks {#S9}
==================

In the past decade(s) many studies have been devoted to delineate the dynamic role of TGF-β signaling in the multistep process of metastasis. While substantial insights were obtained, new layers of complexity and regulation continue to be discovered. Its potent pro-oncogenic activities have been targeted using a scale of selective pharmacological inhibitors. Reported results in cancer models have been very promising. Yet, outcomes observed in more than 20 cancer clinical trials using anti-TGF-β therapies lack consistency and fail to recapitulate the preclinical data, raising questions about what is missing when translating these strategies from bench-to-bedside.

TGF-β function in cancer cell invasion and metastasis is pleiotropic and dynamically controlled. These critical aspects are somewhat overlooked when TGF-β targeting agents are applied to cancer patients. The administration of these drugs to post-operative patients or patients with advanced cancers could increase the seeding of CTCs and the growth of metastatic lesions by blocking its anti-MET activity and its tumor-suppressor function. Also, affected by the activity of antagonist molecular pathways, induced by surrounding elements in the TME and other cancer cells, the dynamics of TGF-β signaling might change from normal to malignant cells (and even from early to late-stage cancer cells) thereby influencing how different patients (or different cells in the same patient) respond to the therapy. Finally, the presence of TGF-β in exosomes could make it inaccessible from antibodies and ligand traps, limiting the effectiveness of these intervention strategies to the freely soluble ligand form of this cytokine. New *in vitro* and *in vivo* models exploiting these points will deepen our knowledge about the real complexity of TGF-β signaling in carcinogenesis. To do so, sensitive technologies such as single cell signaling and live signaling *in vitro* and *in vivo* are to be employed ([@B125]; [@B68]; [@B18]) and further developed. Moreover, clinical trials combining anti-TGF-β therapies to other target therapies such as immune checkpoint inhibitors, or strategies allowing a more spatio-temporal controlled intervention using nanocarriers, may allow for an improved treatment and perhaps even cure of cancer patients.
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